Sera Prognostics, Inc. (SERA)
USD 2.91
(-0.68%)
USD 2.91
(-0.68%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 306 Thousand USD | 14.18% |
| 2022 | 268 Thousand USD | 226.83% |
| 2021 | 82 Thousand USD | 228.0% |
| 2020 | 25 Thousand USD | -30.56% |
| 2019 | 36 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | 24 Thousand USD | 0.0% |
| 2023 Q1 | 100 Thousand USD | 53.85% |
| 2023 FY | 306 Thousand USD | 14.18% |
| 2023 Q3 | 42 Thousand USD | -65.85% |
| 2023 Q2 | 123 Thousand USD | 23.0% |
| 2023 Q4 | 41 Thousand USD | -2.38% |
| 2022 Q2 | 78 Thousand USD | 105.26% |
| 2022 Q1 | 38 Thousand USD | 46.15% |
| 2022 Q4 | 65 Thousand USD | -25.29% |
| 2022 FY | 268 Thousand USD | 226.83% |
| 2022 Q3 | 87 Thousand USD | 11.54% |
| 2021 Q2 | 20 Thousand USD | 53.85% |
| 2021 FY | 82 Thousand USD | 228.0% |
| 2021 Q4 | 26 Thousand USD | 13.04% |
| 2021 Q1 | 13 Thousand USD | 116.67% |
| 2021 Q3 | 23 Thousand USD | 15.0% |
| 2020 Q2 | 6000.00 USD | -25.0% |
| 2020 Q1 | 8000.00 USD | 0.0% |
| 2020 Q4 | 6000.00 USD | 20.0% |
| 2020 FY | 25 Thousand USD | -30.56% |
| 2020 Q3 | 5000.00 USD | -16.67% |
| 2019 FY | 36 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 31.24 Million USD | 99.021% |
| Biodesix, Inc. | 49.08 Million USD | 99.377% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | 87.917% |
| Castle Biosciences, Inc. | 219.78 Million USD | 99.861% |
| DarioHealth Corp. | 20.35 Million USD | 98.496% |
| Exact Sciences Corporation | 2.49 Billion USD | 99.988% |
| IDEXX Laboratories, Inc. | 3.66 Billion USD | 99.992% |
| Illumina, Inc. | 4.5 Billion USD | 99.993% |
| Intelligent Bio Solutions Inc. | 3.11 Million USD | 90.166% |
| iSpecimen Inc. | 9.92 Million USD | 96.918% |
| Standard BioTools Inc. | 106.34 Million USD | 99.712% |
| 23andMe Holding Co. | 219.63 Million USD | 99.861% |
| Medpace Holdings, Inc. | 1.88 Billion USD | 99.984% |
| NeoGenomics, Inc. | 591.64 Million USD | 99.948% |
| Inotiv, Inc. | 572.42 Million USD | 99.947% |
| Psychemedics Corporation | 22.09 Million USD | 98.615% |
| Prenetics Global Limited | 21.74 Million USD | 98.593% |
| Precipio, Inc. | 15.19 Million USD | 97.986% |
| RadNet, Inc. | 1.61 Billion USD | 99.981% |
| Sotera Health Company | 1.04 Billion USD | 99.971% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 99.332% |
| Exagen Inc. | 52.54 Million USD | 99.418% |
| Natera, Inc. | 1.08 Billion USD | 99.972% |
| Aspira Women's Health Inc. | 9.15 Million USD | 96.657% |
| Neogen Corporation | 924.22 Million USD | 99.967% |
| Myriad Genetics, Inc. | 678.4 Million USD | 99.955% |
| ICON Public Limited Company | 8.12 Billion USD | 99.996% |
| Bionano Genomics, Inc. | 36.11 Million USD | 99.153% |
| CareDx, Inc | 280.32 Million USD | 99.891% |
| Check-Cap Ltd. | - USD | -Infinity% |
| Twist Bioscience Corporation | 312.97 Million USD | 99.902% |
| Guardant Health, Inc. | 563.94 Million USD | 99.946% |
| BioNexus Gene Lab Corp. | 9.77 Million USD | 96.868% |
| Fulgent Genetics, Inc. | 289.21 Million USD | 99.894% |
| OPKO Health, Inc. | 863.49 Million USD | 99.965% |
| Personalis, Inc. | 73.48 Million USD | 99.584% |
| Applied DNA Sciences, Inc. | 13.36 Million USD | 97.711% |
| Star Equity Holdings, Inc. | 45.78 Million USD | 99.332% |
| MDxHealth SA | 70.19 Million USD | 99.564% |
| Prenetics Global Limited | 21.74 Million USD | 98.593% |
| ENDRA Life Sciences Inc. | - USD | -Infinity% |
| Mainz Biomed B.V. | 895.47 Thousand USD | 65.828% |
| Trinity Biotech plc | 56.83 Million USD | 99.462% |
| Neuronetics, Inc. | 71.34 Million USD | 99.571% |
| bioAffinity Technologies, Inc. | 2.53 Million USD | 87.917% |